Filtered By:
Specialty: Cardiology
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date.
Order by Relevance | Date
Total 188 results found since Jan 2013.
Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week
J Am Coll Cardiol. 2023 Aug 15;82(7):648-660. doi: 10.1016/j.jacc.2023.05.055.ABSTRACTAmong statin-treated patients, inflammation assessed by means of high-sensitivity C-reactive protein (hsCRP) is a more powerful determinant of cardiovascular death and all-cause mortality than low-density-lipoprotein cholesterol (LDL-C). Several therapies that target residual inflammatory risk significantly reduce vascular event rates. For coronary artery disease patients already taking guideline-directed medical care, including statins, low-dose colchicine (0.5 mg/d orally) has been shown to safely lower major adverse cardiovascular even...
Source: Atherosclerosis - August 9, 2023 Category: Cardiology Authors: Kyle Nelson Valentin Fuster Paul M Ridker Source Type: research
Plain language summary of results from ORION-10 and ORION-11: Two studies to learn how well inclisiran works in people with high cholesterol
Future Cardiol. 2023 Jun 6. doi: 10.2217/fca-2022-0133. Online ahead of print.ABSTRACTWHAT IS THIS PLAIN LANGUAGE SUMMARY ABOUT?: This is a summary of the article describing the results of the ORION-10 and ORION-11 studies, which was published in the New England Journal of Medicine in April 2020. The studies included adult participants with atherosclerotic cardiovascular disease (ASCVD). ASCVD happens when the blood vessels that carry blood from the heart to other areas of the body are blocked by fatty build-up (plaque) causing a heart attack, stroke, or other problems. High levels of low-density lipoprotein cholesterol (L...
Source: Atherosclerosis - June 7, 2023 Category: Cardiology Authors: Kausik K Ray R Scott Wright Source Type: research
Transcatheter Left Atrial Appendage Closure
Methodist Debakey Cardiovasc J. 2023 May 16;19(3):67-77. doi: 10.14797/mdcvj.1215. eCollection 2023.ABSTRACTAtrial fibrillation is the most common arrhythmia worldwide, placing a large population at risk for potentially disabling ischemic strokes, yet an estimated 50% of eligible patients cannot tolerate or are contraindicated to receive oral anticoagulation. Within the last 15 years, transcatheter options for left atrial appendage closure (LAAC) have provided a valuable alternative to chronic oral anticoagulation for reducing risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. With newer...
Source: Methodist DeBakey Cardiovascular Journal - May 22, 2023 Category: Cardiology Authors: Gordon X Wong Gagan D Singh Source Type: research
